TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial
We administered three cycles FOLFOX4 plus TAC(oxaliplatin,FUDR and MMC) or FOLFOX4 plus
TACE(oxaliplatin,FUDR,MMC and embolision) to primary colorectal tumor resected patients with
unresected liver metastasis. The study endpoints were resection rate of liver metastasis,
progression-free survival, overall survival as evaluated by intent-to-treat analysis.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
5 years after operation
No
jianmin xu, MD, PHD
Study Director
department of general surgery, zhongshan hospital, fudan university
China: Ministry of Health
2009-03
NCT00868569
January 2008
December 2010
Name | Location |
---|